Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: A study of polymorphic human xenobiotic-metabolizing enzymes

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2903-2908

  Longuemaux, Sandrine ^a   Deloménie, Claudine ^a   Gallou, Catherine ^b   Méjean, Arnaud ^b   Vincent Viry, Monique ^c   Bouvier, Raymonde ^d   Droz, Dominique ^b   Krishnamoorthy, Rajagopal ^a   Galteau, Marie Madeleine ^c   Junien, Claudine ^b   Béroud, Christophe ^b   Dupret, Jean Marie ^a,e  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Centre de Medecine Preventive   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; ETHOXYRESORUFIN DEETHYLASE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; XENOBIOTIC METABOLISM;

ADULT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; KIDNEY NEOPLASMS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; XENOBIOTICS;

EID: 0344780903     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Motzer, R. J., Bander, N. H., and Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med., 335: 865-875, 1996.
2. Fleming, S. Genetics of renal minors. Cancer Metastasis Rev., 16: 127-140, 1997.
3. Erlandsson, R. Molecular genetics of renal cell carcinoma. Cancer Genet. Cytogenet., 104: 1-18, 1998.
4. Decker, H. J. H., Weidt, E. J., and Brieger, J. The von Hippel-Lindau tumor suppressor gene. Cancer Genet. Cytogenet., 93: 74-83, 1997.
5. Trash-Bingham, C. A., Salazar, H., Freed, J. J., Greenberg, R. E., and Tartof, K. D. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res., 55: 6189-6195, 1995.
6. Godley, P. A., and Escobar, M. A. Renal cell carcinoma. Curr. Opin. Oncol., 10: 261-265, 1998.
7. Yu, M. C., Mack, T. M., Hanisch, R., Cicioni, C., and Henderson, B. E. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J. Natl. Cancer Inst., 77: 351-356, 1986.
8. Yuan, J-M., Castelao, J. E., Gago-Dominguez, M., Yu, M. C., and Ross, R. K. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol. Biomark. Prev., 7: 429-433, 1998.
9. Mellemgaard, A., Lindblad, P., Schlehofer, B., Bergström, R., Mandel, J. S., Mc-Credie, M., McLaughlin, J. K., Niwa, S., Odaka, N., Pommer, W., and Olsen, J. H. International renal-cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines. Int. J. Cancer, 60: 350-354, 1995.
10. Chow, W-H., Gridley, G., McLaughlin, J. K., Mandel, J. S., Wacholder, S., Blot, W. J., Niwa, S., and Fraumeni, J. F., Jr. Protein intake and risk of renal cell cancer. J. Natl. Cancer Inst., 86: 1131-1139, 1994.
11. Wolk, A., Gridley, G., Niwa, S., Lindblad, P., McCredie, M., Mellemgaard, A., Mandel, J. S., Wahrendorf, J., McLaughlin, J. K. and Adami, H-O. International renal cell cancer study. VII. Role of diet. Int. J. Cancer, 65: 67-73, 1996.
12. McLaughlin, J. K., Chow, W. H., Mandel, J. S., Mellemgaard, A., McCredie, M., Lindblad, P. Schlehofer, B., Pommer, W., Niwa, S., and Adami, H-O. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int. J. Cancer., 63: 216-221, 1995.
13. Mandel, J. S., McLaughlin, J. K., Schlehofer, B., Mellemgaard, A., Helmert, U., Lindblad, P., McCredie, M., and Adami, H-O. International renal-cell cancer study. IV. Occupation. Int. J. Cancer, 61: 601-605, 1995.
14. Nebert, D. W., McKinnon, R. A., and Puga, A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol., 15: 273-280, 1996.
15. Gonzalez, F. J. The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Reprod. Toxicol., 11: 397-412, 1997.
16. Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N., and Watanabe, J. Identification of genetically high-risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450 1A1 gene. FEBS Lett., 263: 131-133, 1990.
17. Drakoulis, N., Cascorbi, I., Brockmöller, J., Gross, C. R., and Roots, I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin. Invest., 72: 240-248, 1994.
18. Brockmöller, J., Cascorbi, I., Kerb, R., and Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56: 3915-3925, 1996.
19. Kivistö, K. T., Griese, E-U., Stüven, T., Fritz, P., Friedel, G., Kroemer, H. K., and Zanger, U. M. Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics, 7: 295-302, 1997.
20. Rosvold, E. A., McGlynn, K. A., Lustbader, E. D., and Buetow, K. H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 5: 199-206, 1995.
21. Rauth, A. M., Goldberg, Z., and Misra, V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol. Res., 9: 339-349, 1997.
22. Rebbeck, T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 6: 733-743, 1997.
23. Strange, R. C., Lear, J. T., and Fryer, A. A. Glutathione S-transferase polymorphisms: influence on susceptibility to cancer. Chem. Biol. Interact., 111-112: 351-364, 1998.
24. Chen, H., Sandler, D. P., Taylor, J. A., Shore, D. L., Liu, E., Bloomfield, C. D., and Bell, D. A. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase θ 1 (GSTT1) gene defect. Lancet, 347: 295-297, 1996.
25. Ali-Osman, F., Akande, O., Antoun, G., Mao, J-X., and Buolamwini, J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. J. Biol. Chem., 272; 10004-10012, 1997.
26. Harries, L. W., Stubbins, M. J., Forman, D., Howard, G. C. W., and Wolf, C. R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (Lond.), 18: 641-644, 1997.
27. Harris, M. J., Coggan, M., Langton, L., Wilson, S. R., and Board, P. G. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics, 8: 27-31, 1998.
28. Lang, N. P. Acetylation as an indicator of risk. Environ. Health Perspect., 105 (Suppl. 4): 763-766, 1997.
29. Roberts-Thomson, I. C., Ryan, P., Khoo, K. K., Hart, W. J., McMichael, A. J., and Butler, R. N. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet, 347: 1372-1374, 1996.
30. Thoenes, W., Storkel, S., and Rumpelt, H. J. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol. Res. Pract., 181: 125-143, 1986.
31. Béroud, C., Fournet, J. C., Jeanpierre, C., Droz, D., Bouvier, R., Froger, D., Chrétien, Y., Maréchal, J-M., Weissenbach, J., and Junien, C. Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas. Genes Chromosomes Cancer, 17: 215-224, 1996.
32. Bailey, L. R., Roodi, N., Verrier, C. S., Yee, C. J., Dupont, W. D., and Parl, F. F. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res., 58: 65-70, 1998.
33. Sachse, C., Brockmöller, J., Bauer, S., and Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60: 284-295, 1997.
34. Steen, V. M., Andreassen, O. A., Daly, A. K., Tefre, T., Borresen, A-L., Idle, J. R., and Gulbrandsen, A-K. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics, 5: 215-223, 1995.
35. Schulz, W. A., Krummeck, A., Rösinger, I., Eickelmann, P., Neuhaus, C., Ebert, T., Schmitz-Dräger, B. J., and Sies, H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7: 235-239, 1997.
36. Gaedigk, A., Tyndale, R. F., Jurima-Romet, M., Sellers, E. M., Grant, D. M., and Leeder, J. S. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics, 8: 305-313, 1998.
37. Deloménie, C., Mathelier-Fusade, P., Longuemaux, S., Rozenbaum, W., Leynadier, F., Krishnamoorthy, R., and Dupret, J-M. Glutathione S-transferase (GSTM1) null genotype and sulphonamide intolerance in acquired immunodeficiency syndrome. Pharmacogenetics, 7: 519-520, 1997.
38. Arand, M., Mühlbauer, R., Hengstler, J., Jäger, E., Fuchs, J., Winkler, L., and Oesch, F. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal. Biochem., 236: 184-186, 1996.
39. Fryer, A. A., Zhao, L., Alldersea, J., Pearson, W. R., and Strange, R. C. Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1A, B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochem. J., 295: 313-315, 1993.
40. Deloménie, C., Sica, L., Grant, D. M., Krishnamoorthy, R., and Dupret, J-M. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics, 6: 177-185, 1996.
41. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. The analysis of case-control studies IARC Scientific Publ. No. 32. Lyon, France: IARC, 1980.
42. Cascorbi, I., Brockmöller, J., and Roots, I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res., 56: 4965-4969, 1996.
43. Griese, E-U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Mörike, K., Stüven, T., and Eichelbaum, M. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics, 8: 15-26, 1998.
44. Bartsch, H., Malaveille, C., Lowenfels, A. B., Maisonneuve, P., Hautefeuille, A., Boyle, P., and the International Pancreatic Disease Study Group. Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. Eur. J. Cancer Prev., 7: 215-223, 1998.
45. Elexpuru-Camiruaga, J., Buxton, N., Kandula, V., Dias, P. S., Campbell, D., McIntosh, J., Broome, J., Jones, P., Inskip, A., Alldersea, J., Fryer, A. A., and Strange, R. C. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res., 55: 4237-4239, 1995.
46. Matthias, C., Bockmühl, U., Jahnke, V., Harries, L. W., Wolf, C. R., Jones, P. W., Alldersea, J., Worrall, S. F., Hand, P., Fryer, A. A., and Strange, R. C. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics, 8: 1-6, 1998.
47. Agúndez, J. A. G., Olivera, M., Ladero, J. M., Rodriguez-Lescure, A., Ledesma, M. C., Diaz-Rubio, M., Meyer, U. A., and Benítez, J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics. 6: 501-512, 1996.
48. Hubbard, A. L., Harrison, D. J., Moyes, C., Wyllie, A. H., Cunningham, C., Mannion, E., and Smith, C. A. D. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut. 41: 229-234, 1997.
49. Schnakenberg, E., Ehlers, C., Feyerabend, W., Werdin, R., Hübotter, R., Dreikorn, K., and Schloot, W. Genotyping of the polymorphic W-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin. Genet., 53: 396-402, 1998.
50. Droll, K., Bruce-Mensah, K., Otton, S. V., Gaedigk, A., Sellers, E. M., and Tyndale, R. F. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics, 8: 325-333, 1998.
51. Joseph, P., and Jaiswal, A. K. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones. Br. J. Cancer, 77: 709-719, 1998.
52. Brüning, T., Lammert, M., Kempkes, M., Thier, R., Golka, K., and Bolt, H. M. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch. Toxicol., 71: 596-599, 1997.
53. Brüning, T., Weirich, G., Hornauer, M. A., Höfler, H., and Brauch, H. Renal cell carcinomas in trichloroethene (TRI) exposed persons are associated with somatic mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. Arch. Toxicol., 71: 332-335, 1997.
54. Vaury, C., Lainé, R., Noguiez, P., de Coppet, P., Jaulin, C., Praz, F., Pompon, D., and Amor-Guéret, M. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res., 55: 5520-5523, 1995.
55. Sherratt, P. J., Pulford, D. J., Harrison, D. J., Green, T., and Hayes, J. D. Evidence that human class θ glutathione S-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. Biochem. J., 326: 837-846, 1997.
56. Rintala, S., Tammela, T. L. J., and Tuimala, R. CYP1A1 activity in renal cell carcinoma and in adjacent normal renal tissue. Urol. Res., 26: 117-121, 1998.
57. Klöne, A., Weidner, U., Hußnätter, R., Harris, J., Meyer, D., Peter, S., Ketterer, B., and Sies, H. Decreased expression of the glutathione S-transferases α and pi genes in human renal cell carcinoma. Carcinogenesis (Lond.), 11: 2179-2183, 1990.
58. Okkels, H., Sigsgaard, T., Wolf, H., and Autrup, H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomark. Prev., 6: 225-231, 1997.
59. d'Errico, A., Taioli, E., Chen, X., and Vineis, P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers, 1: 149-173, 1996.
60. Kempkes, M., Golka, K., Reich, S., Reckwitz, T., and Bolt, H. M. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch. Toxicol., 71: 123-126, 1996.
61. Okkels, H., Sigsgaard, T., Wolf, H., and Autrup, H. Glutathione S-transferase μ as a risk factor in bladder tumors. Pharmacogenetics, 6: 251-256, 1996.
62. Hirvonen, A., Nylund, L., Kociba, P., Husgafvel-Pursiainen, K., and Vainio, H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis (Lond.), 15: 813-815, 1994.
63. Chinegwundoh, F. I., and Kaisary, A. V. Polymorphism and smoking in bladder carcinogenesis. Br. J. Urol., 77: 672-675, 1996.
64. Badawi, A. F., Stern, S. J., Lang, N. P., and Kadlubar, F. F. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. Prog. Clin. Biol. Res., 395: 109-140, 1996.
65. Ross, R. K., Jones, P. A., and Yu, M. C. Bladder cancer epidemiology and pathogenesis. Semin. Oncol., 23: 536-545, 1996.